INDIANAPOLIS, Nov. 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today patients with active psoriatic arthritis (PsA) treated with Taltz ® (ixekizumab), who were previously ...

INDIANAPOLIS, June 16, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz ® (ixekizumab) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Taltz was effective treatment for ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Taltz injection for treating moderate-to-severe plaque psoriasis in adults who are ...

* Eular 2017: Lilly's Taltz (ixekizumab) demonstrated significant improvements in disease signs and symptoms at 24 weeks among patients with active psoriatic arthritis who had prior inadequate ...

Eli Lilly's Taltz and Novartis' Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come out on ...

Eli Lilly reported that Taltz (ixekizumab) achieved primary and secondary endpoints in SPIRIT-P2, a Phase 3 clinical trial evaluating the treatment in psoriatic arthritis (PsA). These results were ...

TALTZ The FDA has approved the supplemental Biologics License Application (sBLA) for Taltz (ixekizumab: Lilly) injection for the treatment of pediatric patients aged ≥6 years with moderate to severe ...

Eli Lilly and Co. has won federal approval to market its hot-selling anti-inflammatory drug Taltz for another use: treatment of a type of arthritis that does not show any structural body damage on ...

A man and a woman are barefoot on a couch, snuggling and smiling. In the background, a guitar starts strumming. “When you’re close to the people you love,” the television announcer says, “does ...